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Treatment of endobronchial metastases with
intraluminal radiotherapy
S. J. QUANTRILL*, P. A., BURT{, P. V. BARBER* AND R. STOUT{
*North West Lung Centre and {Christie Hospital and Holt Radium Institute, Manchester, U.K.
Metastasis to the lung occurs quite commonly from certain types of extrapulmonary primary carcinoma. Spread to
the bronchial lumen is relatively rare. When this does occur, symptoms resembling those of primary bronchial
carcinoma are often present, in association with partial or complete obstruction of the bronchial lumen. Palliation
of such symptoms is possible with the use of intraluminal radiotherapy (ILT). Between 1990 and 1998, 37 patients
with endobronchial metastases were treated using this modality; a single fraction of radiation was delivered by the
remote afterloading high dose rate microSelectron system. Data regarding these patients’ characteristics and
outcome are presented, following a retrospective review of case notes.
The commonest symptoms were dyspnoea, cough and haemoptysis; the commonest primary tumour sites were
breast, colorectum, oesophagus and kidney. Twenty-four (649%) patients had some improvement in symptoms
following treatment. Mean overall survival was 280 days, range 9–1145 days. No serious adverse eects occurred.
ILT is a relatively simple, safe and eective treatment in the palliation of symptoms due to endobronchial
metastases.
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Endobronchial metastases from extrapulmonary primary
tumours are rare (1). Symptoms may be indistinguishable
from those of primary bronchial carcinoma and obstruction
of the bronchial lumen may result in partial or complete
collapse of the lung. Various treatments are available for
removal or reduction of the endobronchial tumour with
restoration of airway patency; our patients were treated
with ILT. These patients’ characteristics, symptoms, benefit
from treatment and survival are presented following a
retrospective review of their case records.
Patient characteristics, clinical
features, treatment and outcome
PATIENT CHARACTERISTICS
Thirty-seven patients (15 male, 22 female) with endobron-
chial metastases presenting to the Christie Hospital,
Manchester (a regional cancer centre) between 1990 and
1998 were included in the study. Mean age was 619 years,Received 3 May 1999 and accepted in revised form 26 October
1999.
Correspondence should be addressed to Dr S. J. Quantrill, Chest
Clinic, Whipps Cross Hospital, Leytonstone, London E11 1NR,
U.K.
0954-6111/00/040369+04 $35?00/0range 23–82 years. Four patients had undergone external
beam radiotherapy to the lung and nine had received
systemic chemotherapy or hormone therapy months or
years prior to ILT. One patient had an endobronchial
surgical debulking procedure after ILT. No patients had
any other prior local treatment such as laser or cryother-
apy. Three patients were lost to follow-up, dates of death in
these cases being ascertained from family health authority
statistics.
CLINICAL FEATURES
The most common symptoms were dyspnoea, haemoptysis
and cough. The commonest primary tumours were found in
breast, colorectum, oesophagus and kidney (Table 1). The
time from diagnosis of the primary tumour to presentation
of endobronchial metastasis (recurrence interval) could
often amount to several years. One patient with adeno-
carcinoma of the stomach presented initially with an
endobronchial lesion, the primary tumour being discovered
some weeks later following an episode of haematemesis.
The patient with malignant melanoma did not present until
44 years after surgical excision of a primary skin lesion.
Endobronchial tumours were mostly situated in the larger
proximal airways and occurred more often on the right side
of the bronchial tree than the left (Table 2).
Synchronous extrabronchial metastases were common,
occurring in 27 (75%) patients (excluding one patient
with generalized Hodgkin’s lymphoma, a condition# 2000 HARCOURT PUBLISHERS LTD
TABLE 1. Site of primary tumour, recurrence interval, presence of extrabronchial disease and survival
Primary tumour No. of patients Recurrence interval (months) Extrabronchial
tumour
Survival (days)
Mean Range Mean Range
Breast 8 80 9–222 5 311 9–640
Colorectum 8 44 0–99 5 237 43–879
Oesophagus 6 40 11–88 3 208 53–383
Kidney 5 79 12–159 3 318 110–670
Cervix 2 23 18–29 1 141 93–189
Stomach 1 0 1 134
Bladder 1 25 1 304
Melanoma 1 (44 years) 1 47
Hodgkin’s 1 55 — 1145
Pleomorphic adenoma 1 98 1 133
Thyroid 1 182 1 506
Endometrium 1 69 1 164
Ewing’s sarcoma 1 23 1 120
TABLE 2. Site of endobronchial tumour
Site n
Trachea 4
Right main/intermediate bronchus 19
Right lower lobe 7
Right middle lobe 3
Right upper lobe 6
Left main bronchus 8
Left lower lobe 4
Left upper lobe 4
Lingula 1
Bilateral 7
TABLE 3. Site of extrabronchial tumour








370 S. J. QUANTRILL ET AL.characterized by widespread tumour). The most common
sites for these lesions were lung, bone and lymph nodes
(Table 3).
TREATMENT
Twenty-nine patients were treated with a single fraction of
15 Gy at 1 cm radius from the radioactive source using the
high dose rate microSelectron (Nucletron Trading Ltd).
Two patients received single doses of 10 Gy each and one
patient 20 Gy. Five patients had combinations of 15/10 Gy
to bilateral tumours. Patients first underwent fibreoptic
bronchoscopy using local anaesthesia, in order to locate the
lesion. A 2 mm diameter brachytherapy applicator was
inserted via the suction channel of the bronchoscope and
passed distal to the tumour, or, if this were not possible,
adjacent to it. A guide wire was then placed inside the
applicator and the bronchoscope removed, leaving the
applicator in situ. This was then secured to the patient’s
nose with tape. The guide wire was then replaced by a wiregraduated with 1 cm radio opaque markers which was
advanced to the tip of the catheter. Plain chest radiographs
were taken in antero-posterior and lateral views to verify
the position of the brachytherapy applicator and plan the
radiotherapy treatment. The graduated wire was removed
and the applicator was then attached to the microSelectron
safe from which the radioactive source (iridium-192) was
delivered. The source was advanced in 5mm steps at a rate
of approximately 1 cm min71, resulting in a total treatment
time of approximately 10 min, the entire procedure being
monitored throughout in an adjacent shielded room using
closed circuit television. Patients were allowed home the
same day. No adverse eects were observed at any time
either during or after treatment.
OUTCOME
Symptoms were improved by treatment in 24 (649%)
patients (Table 4), most notably with respect to haemop-
tysis which was abolished in 67% of cases. Improvement
occurred even in patients with very short-term survival and
patients with advanced cancer benefited, as did those at an
earlier stage. Survival was generally poor, but widely
variable (Table 1), and tended to be longer in those patients
with no overt extrabronchial metastases compared with
those who did have other metastases (median survival 339
vs. 138 days, P=021). Four patients are still alive at the
time of writing, 212–670 days after receiving ILT. Age had
no significant eect on survival.
TABLE 4. Symptoms
Symptoms No. of patients No. of patients
(%) improved
Dyspnoea 24 10 (42)
Haemoptysis 18 12 (67)
Cough 16 8 (50)
Wheeze 6 2 (33)
Stridor 3 1 (33)
ENDOBRONCHIAL METASTASES TREATMENT WITH RADIOTHERAPY 371Discussion
Whilst metastases to lung are common from various
primary tumours, spread to the bronchial tree is relatively
rare, with a probable incidence of around 2% of solid
tumours (1). The diagnosis may be overlooked, especially if
the chest radiograph is normal, and can only be made if
bronchoscopy is undertaken. The largest reported series of
such patients studied in detail contained 25 cases, 10 of
whom had surgical resections (2).
The endobronchial lesion may develop by invasion from
surrounding tissue (e.g. lung parenchyma, oesophagus), or
by direct seeding within the bronchial wall (3). Such
tumours may give rise to symptoms identical to those of
primary bronchial carcinoma, including stridor if situated
centrally, and partial or complete collapse of a lung may
also occur (4,5). They may, however, be asymptomatic (6).
In most series, the commonest primary tumours are
breast, colon and kidney (6,7). We have also found
oesophageal carcinoma to be a common primary site,
which might be expected from the proximity of the
oesophagus to the tracheobronchial tree.
In general, the treatment of endobronchial tumours can
provide relief of symptoms and re-expansion of atelectatic
lung (8–11). In patients with primary bronchial carcinoma,
tumour reduction with restoration of airway patency results
in significant improvement in ventilation and perfusion and
in spirometry, 6 min walking distance, dyspnoea, perfor-
mance status and well-being (12).
Various management options are available for treating
localized endobronchial tumours and include surgery (2),
external beam radiotherapy, ILT (10,11,13715), laser
therapy (16,17), cryotherapy (18,19), electrocautery (20),
mechanical removal with a rigid bronchoscope (21) and
photodynamic therapy (22). Stents may be inserted follow-
ing treatment of the tumour in order to maintain airway
patency (17). Combinations of these various treatments
have been used and found to be complementary in someinstances, examples being laser therapy followed by ILT or
photodynamic therapy (23) and cryotherapy plus external
beam radiotherapy (24).
In our series ILT alone was found to benefit nearly two-
thirds of patients with endobronchial metastases. This is
likely to be an underestimate, as three of our patients were
initially lost to follow-up. One of these patients, with renal
cell carcinoma, survived over 2 years from treatment, but
we were unable to follow him up to assess symptomatic
improvement. The assessment of symptom relief was also
complicated by the presence of parenchymal lung metas-
tases in 15 patients, pleural deposits in another and hilar or
mediastinal adenopathy in others. We did not repeat
bronchoscopy to assess tumour reduction because we were
mainly interested in symptomatic response [response to ILT
as evaluated by direct visualization of tumour has been
assessed with primary bronchial carcinoma and found to be
significant (10,13)]. The treatment was easy to administer,
well-tolerated, requiring only a single standard fibreoptic
bronchoscopy procedure, and patients were discharged
home the same day. General anaesthesia, with its attendant
risks (especially in the elderly and those with more
advanced disease), was not required.
Only one fraction of radiotherapy needs to be given,
reducing the amount of time spent in hospital. A single dose
of 15 Gy at 1 cm from the source has been extensively
evaluated in the treatment of primary bronchial carcinoma
and produces good palliation with minimal morbidity (14).
The bronchoscopy catheter placement and actual radio-
therapy are all short procedures and further bronchoscopy
is not usually required. However, unlike external beam
radiotherapy, ILT can be repeated if necessary because of
the lower radiation doses employed (13). As with cryother-
apy and photodynamic therapy ILT results in an improve-
ment in airway patency within days, but not immediately: it
is not therefore suitable for treating near-complete ob-
structive lesions of the trachea which are imminently life
threatening. In this latter situation, laser therapy or
preliminary stenting maybe appropriate. (16,17).
ILT has an advantage over external beam radiotherapy
in that a high dose of radiation can be delivered to a small
area with minimal side-eects and with little or no damage
to surrounding tissue. This is particularly useful in those
patients with already compromised cardiac or pulmonary
function and in patients pre-treated with external beam
radiation. The serious complication rate from ILT is low
and is mainly due to massive haemoptysis occurring
especially when higher total radiation doses are used or
additional laser therapy (25). However, this may also result
from the tumour itself and is a late complication occurring
some months after treatment, and in this respect is less
relevant in this group of patients, many of whom have
relatively shortened survival. The use of a single 15 Gy dose
when used alone in bronchial carcinoma was not associated
with an increased risk of massive fatal haemoptysis (25).
Other adverse eects include immediate pneumothorax
secondary to brachytherapy catheter insertion and fistula
formation, occurring some months after treatment. None of
these complications were observed in our patients, possibly
in part because we limited treatment to a single procedure,
372 S. J. QUANTRILL ET AL.radiation doses were low, relatively few patients were
treated with additional external beam radiotherapy and
none with laser therapy.
In conclusion, the possibility of endobronchial metastasis
should always be considered in any patient with a past or
current history of malignancy presenting with symptoms of
dyspnoea, cough, haemoptysis, wheeze, stridor or recurrent
pneumonia. ILT is a simple, eective, well-tolerated and safe
procedure which can benefit patients with endobronchial
metastases in both early and advanced stages of cancer.
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